Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CPA1 | P15085 | 6/20 | 0.53 |
| ▸ | CPA3 | P15088 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080776 | 1.00 | CYP1A2 (0.59) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7080774 | 1.00 | CYP1A2 (0.59) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL29811096 | 0.93 | PPARG (0.52) | CYP1A2CPA1CPA3FOLH1NAALAD2 | |
| SCHEMBL29506214 | 0.91 | CYP1A2 (0.49) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL16898375 | 0.84 | NPC1 (0.44) | CYP1A2FOLH1SLC1A3SLC1A1 | |
| SCHEMBL16898377 | 0.84 | NPC1 (0.44) | CYP1A2FOLH1SLC1A3SLC1A1 | |
| SCHEMBL7277804 | 0.83 | ACE2 (0.46) | FOLH1SLC1A1 | |
| SCHEMBL3319286 | 0.81 | PTGES (0.48) | FOLH1 | |
| SCHEMBL4955699 | 0.81 | PTGES (0.48) | FOLH1 | |
| SCHEMBL134381 | 0.80 | CTRC (0.48) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140058-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARM (GB) | 2003-11-05 | — | — | EP | disclosed |
| US-20030149084-A1 | Cytostatic agents | AYSCOUGH ANDREW PAUL (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6495597-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2002-12-17 | — | — | US | disclosed |
| US-6476067-B1 | N-formyl hydroxylamine derivatives as antibacterial agents | BRITISH BIOTECH (GB) | 2002-11-05 | — | — | US | disclosed |
| EP-1146868-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| EP-1140058-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| EP-1054861-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000043001-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000035440-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999041232-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149084-A1 | Cytostatic agents | MCTS1, NNMT, MMP12 | CYP1A2 3623/4885CPA1 429/4885CPA3 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.